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).a b s t r a c t
Sub-chronic toxicity studies of 163 non-genotoxic chemicals were evaluated in order to predict the
tumour outcome of 24-month rat carcinogenicity studies obtained from the EFSA and ToxRef databases.
Hundred eleven of the 148 chemicals that did not induce putative preneoplastic lesions in the sub-
chronic study also did not induce tumours in the carcinogenicity study (True Negatives). Cellular hy-
pertrophy appeared to be an unreliable predictor of carcinogenicity. The negative predictivity, the
measure of the compounds evaluated that did not show any putative preneoplastic lesion in de sub-
chronic studies and were negative in the carcinogenicity studies, was 75%, whereas the sensitivity, a
measure of the sub-chronic study to predict a positive carcinogenicity outcome was only 5%. The
speciﬁcity, the accuracy of the sub-chronic study to correctly identify non-carcinogens was 90%. When
the chemicals which induced tumours generally considered not relevant for humans (33 out of 37 False
Negatives) are classiﬁed as True Negatives, the negative predictivity amounts to 97%. Overall, the results
of this retrospective study support the concept that chemicals showing no histopathological risk factors
for neoplasia in a sub-chronic study in rats may be considered non-carcinogenic and do not require
further testing in a carcinogenicity study.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is one of the leading causes of death in industrialized
countries. In those countries the cancer rate has risen from 1 in 10
in 1930 to 1 in 3 today. According to the American Cancer Society,
almost 45% of men and 38% of women will be diagnosed with
cancer at some point in their lives (American Cancer Society, 2014).
Cancer is responsible for 7.6 million deaths worldwide per year,
with 3 million new cancer cases per year in Europe alone (WHO,
2011).
Whilst there is no single cause of cancer, evidence is emerging
that exposures to chemical substances in our everyday life may beUtrechtseweg 48, 3704 HE,
ruud.woutersen@iCloud.com
r Inc. This is an open access articlecontributing to the increasing cancer burden. Past occupational
exposure to known or probable carcinogens is estimated to account
for 5.3% (8023) of cancer deaths and 4% of cancer registration
occurring each year in Great Britain (HSE, 2014).
Industry currently uses thousands of substances that have not
yet been tested for their effect on human health. The EU REACH
(Registration, Evaluation, Authorization and restriction of CHem-
icals) (EC, 2007) aims to evaluate any substance produced or im-
ported in signiﬁcant quantities unless sufﬁcient safety information
already exists. When applying the traditional toxicity tests this will
cost more than 200 years to be completed. In the worst-case sce-
nario, 2.9 million animals would be needed for testing all these
chemicals (Van der Jagt et al., 2004). This is ethically and
economically not defensible. Therefore, alternative methods for
toxicity testing are warranted.
Much of what we know about chemicals and cancer comes from
studies with animals, long-term follow-up of workers exposed to
chemicals at their workplace, and epidemiological studies inunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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Although a number of factors have been related to the induction of
cancer, it is not possible to predict with complete certainty from
animal studies alone which chemicals under which exposure cir-
cumstances will be carcinogenic in humans. The current 2-year
rodent carcinogenicity study (OECD, 2009) has been the regulato-
ry standard in safety assessments of environmental chemicals, and
is presumed to forecast potential long-term human cancer risks of
exposure to industrial chemicals. Under REACH, relevant factors
that may trigger a two-year carcinogenicity bioassay in this respect
include: i) genotoxicity (germ cell mutagen category 2); ii) evidence
of treatment-related hyperplasia and/or preneoplastic lesions in
the sub-chronic study; iii) previous demonstration of carcinogenic
potential in the chemical class or product that is considered rele-
vant to humans; iv) widespread use or evidence of frequent long-
term human exposure.
A positive test result in an in vivo genotoxicity test is generally
considered indicative of the carcinogenic potential of a chemical.
For pharmaceuticals, agrochemicals and most consumer products,
a positive result in an assay for DNA reactivity will usually preclude
further development (ICH, 1995; Snyder and Green, 2001). Under
REACH (EC, 2007), the requirement to perform a carcinogenicity
study is conditional, since the default presumption is that if a
substance is classiﬁed as germ cell mutagen category 1A or 1B, a
genotoxic mechanism for carcinogenicity is likely.
There is, however, considerable scientiﬁc doubt about the reli-
ability of the carcinogenicity bioassay, since too many false positive
outcomes have been observed (Van Oosterhout et al., 1997; Cohen,
2004; Boobis et al., 2009) concerns raised about the predictive
value of in vivo studies in general (Jacobson-Kram et al., 2004;
Anisimov et al., 2005; Billington et al., 2010; Osimitz et al., 2013)
and the push for reﬁnement, reduction, and replacement of animal
studies, resulted in the recommendation to re-evaluate the 2-year
rodent bioassay as the best approach to predict human disease
(Cohen, 2004; Ward, 2007; Boobis et al., 2009; Friedrich and
Olejniczak, 2011; Sistare et al., 2011; Benigni, 2012; Doktorova
et al., 2012; Gori, 2013).
Reddy et al. (2010) and Sistare et al. (2011) concluded that
pharmaceuticals that showed absence of histopathological risk
factors, such as hyperplasia, hypertrophy, foci of cellular alteration,
and cell proliferation, for neoplastic lesions in any tissue in rats in
the 6- or 12-month study may be considered non-carcinogens and
do not require testing in a two-year carcinogenicity study, provided
that these pharmaceuticals lack genotoxic potential and fail to
induce hormonal perturbations.
The sub-chronic (13-week) rat study (OECD, 1998), which in-
cludes endpoints as clinical chemistry and histopathology of awide
range of organs and tissues, is currently required by regulatory
bodies worldwide as the ﬁrst tier in safety testing of foods and
chemicals. In the present paper, we further investigated the hy-
pothesis of Reddy et al. (2010) and Sistare et al. (2011) that chem-
icals showing no histopathological risk factors for carcinogenicity
in an extended sub-chronic toxicity study may be considered non-
carcinogenic (the so called “whole animal negative predictivity
hypothesis”), using 202 chemicals for which adequate data from
sub-chronic (13-week) and carcinogenicity (24-month) studies
were present in the ToxRef EPA- and EFSA database.
2. Materials and methods
2.1. Data sources, and data inclusion and exclusion criteria
The rat sub-chronic toxicity and chronic carcinogenicity data
used for this evaluation came from two different sources: the Eu-
ropean Food Safety Agency (EFSA) database (www.efsa.europa.eu/publications) and the ToxRef EPA database (www.epagov/
pesticides/science/comptox-glossary.html#toxrefdb). The data
used are all publicly available and have been derived from studies
performed according to OECD Test Guidelines.
This evaluation focused on sub-chronic (13-week) toxicity and
carcinogenicity (24-month) studies conducted in rats. The criteria
applied for inclusion of the studies were similar to those reported
previously by Reddy et al. (2010) and Sistare et al. (2011). These are
based on the study outcomes (putative preneoplastic lesions in
sub-chronic studies, and tumours in carcinogenicity studies, resp.)
and the dose levels used. Apart from a few exceptions, the short- en
long-term studies were performed with the same strain of rats.
In short, studies were included in the evaluation when:
 the dose levels in the sub-chronic study showed any overlap
with those of the carcinogenicity study;
 the sub-chronic study was negative (did not demonstrate pu-
tative preneoplastic lesions) at doses higher than those used in
the carcinogenicity study;
 the sub-chronic study was positive (demonstrated putative
preneoplastic histopathological changes) even if the doses were
less than 75% of the doses used in the carcinogenicity study; or
 the sub-chronic study was negative and the top dose was less
than 75% of the top-dose used in the carcinogenicity study, but
lower doses in the carcinogenicity study matched those in de
sub-chronic study and positive tumour ﬁndings occurred.
Substances were excluded on the basis of two criteria:
 the sub-chronic study was positive (demonstrated putative
preneoplastic lesions) only at a dose that was over 25% higher
than the highest dose used in the carcinogenicity study, and
 the highest dose in the sub-chronic study was negative
(demonstrated no putative preneoplastic lesions), but this dose
was less than 25% of the lowest dose in the carcinogenicity
study.2.2. Toxicological evaluation of substances
All substances present in the database were evaluated for the
following parameters: body weight, organ weights, presence of
putative preneoplastic histopathological changes in the sub-
chronic study, treatment-related increased tumour incidences in
the 24-month carcinogenicity studies, and genotoxicity. We have
not included the mode or mechanism of action (e.g. hormonal
perturbation) of the chemicals evaluated.
2.2.1. Histopathological changes
Substances were evaluated for the following histopathological
changes in sub-chronic (13-week) toxicity studies:
- cellular hyperplasia,
- presence of altered hyperplastic foci of cellular alteration
(atypical) cell foci (basophilic; acidophilic foci), and
- cellular proliferation.
- cellular hypertrophy.
In case of induction of cellular hypertrophy, this was recorded
but not included as a putative preneoplastic lesion since an Inter-
national ESTP Expert Workshop recently concluded that cellular
hypertrophy without histopathological or clinical alterations are
generally considered as an adaptive and non-adverse reaction and
not as a step toward carcinogenicity (Hall et al., 2012).
Substances were scored negative when any of the
Table 1
Chemicals evaluated.
Chemicals Genotoxicity
Category N % Negative (%) Positive Inconclusive
True Negative (TN) 134 66 111 (82) 5 18
True Positive (TP) 8 4 2 (25) 5 1
False Positive (FP) 15 8 13 (87) 2 0
False Negative (FN) 45 22 37 (82) 8 0
Total 202 100 163 (81) 20 19
True Negative: sub-chronic study: negative; carcinogenicity study: negative.
True Positive: sub-chronic study: positive; carcinogenicity study: positive.
False Positive: sub-chronic study: positive; carcinogenicity study: negative.
False Negative: sub-chronic study: negative; carcinogenicity study: positive.
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the database. Substances were scored positive when incidences
were higher than in controls, and treatment-related. With no ac-
cess to the original study reports, no attempts were made to re-
evaluate the data. When the histopathological changes were
incorporated in the database, they were considered to be related to
treatment and signiﬁcantly increased.
2.2.2. Organ and body weights
Increased organweights, expressed as an organ-to-body weight
ratio, were collected from 13-week repeated-dose toxicity studies
and considered statistically signiﬁcantly increased when
mentioned as such in the database. Statistical analyses were not
performed as individual data were not available.
2.2.3. Carcinogenicity
Substances were considered positive for carcinogenicity when a
treatment-related increase in benign and/or malignant tumour
incidence in the 2-year bioassay was reported in any of the data-
bases used. Substances were considered negative for carcinoge-
nicity when no increase in tumour incidence in the two-year
bioassay was reported.
2.2.4. Genotoxicity
Genotoxicity data available through TOXNET (http://toxnet.nlm.
nih.gov) were evaluated to assess the genotoxic potential of sub-
stances examined in this study. Data from the following in vitro
genotoxicity assays were taken into consideration: the Ames test
(OECD, 1997a) and/or mammalian cell gene mutation tests (OECD,
1997b) for mutagenicity; the in vitro micronucleus test (OECD,
2014a) and/or the chromosome aberration test (OECD, 2014b) for
clastogenicity. For evidence of in vivo genotoxicity, data from the
following assays were collected: the chromosome aberration test
(OECD, 2014c) and the micronucleus test (OECD, 2014d) in rodents
for chromosomal alterations, the in vivo transgenic rodent gene
mutation assay (OECD, 2013) for mutagenicity, and the in vivo
alkaline comet assay (OECD, 2014e) as indicator for DNA damage.
Substances with a negative in vitro test result for mutagenicity
and clastogenicity were considered to have no genotoxic potential.
Substances with a positive test result in any of the aforementioned
in vitro genotoxicity assays were only scored positive for genotox-
icity if conﬁrmed in an adequate in vivo genotoxicity test. According
to the OECD Test Guidelines, positive results seen only at concen-
trations associated with high levels of cytotoxicity would not be
considered positive. Substances with a positive outcome in any of
the in vivo genotoxicity assays mentioned above that was not
otherwise explained as an irrelevant ﬁnding were considered
genotoxic. Substances with conﬂicting data were scored as
“inconclusive”.
3. Results
In total, 233 substances were evaluated, of which 202 met the
criteria described in the Materials andMethods section for deﬁning
valid pairs of rat sub-chronic and two-year carcinogenicity studies
based on matching dose levels. Thirteen compounds are marketed
nutrients and the rest are marketed chemicals, mainly pesticides.
Based on the results of the 13-week study, the substances were
classiﬁed as follows:
 Substances that induced neither putative preneoplastic histo-
pathological changes in the 13-week study, nor a treatment-
related increase in benign or malignant tumours in the carci-
nogenicity study were classiﬁed as True Negative (TN). Substances that induced both putative preneoplastic histo-
pathological lesions in the 13-week study as well as a
treatment-related increase in benign and/or malignant tumours
in the carcinogenicity study were classiﬁed as True Positive
(TP).
 Substances that induced putative preneoplastic histopatholog-
ical changes in the 13-week study, but no treatment-related
increase in benign and/or malignant tumours in the carcinoge-
nicity study were classiﬁed as False Positive (FP).
 Substances that induced no putative preneoplastic lesions in the
13-week study but a treatment-related increase in benign and/
or malignant tumours in the carcinogenicity study were classi-
ﬁed as False Negative (FN).
Overall, 163 of the 202 (81%) substances were classiﬁed negative
for genotoxicity, whereas 39/202 (19%) scored either positive (10%)
or inconclusive (9%) in the genotoxicity assays (Table 1).
For the present evaluation, we concentrated on non-genotoxic
compounds and excluded substances that were genotoxic or
inconclusive with regard to genotoxicity, since the general pre-
sumption is that genotoxic compounds are carcinogenic and are
presently tested only very occasionally for carcinogenicity in a 24-
month study in rats.
Hundred eleven of the 148 (75%) non-genotoxic substances that
did not induce putative preneoplastic lesions in the 13-week study,
also did not cause treatment-related tumours in the carcinogenicity
study (True Negative compounds), whereas 37 (23%) non-
genotoxic substances that were negative in the 13-week study
showed treatment-related tumours in the carcinogenicity study
(False Negative compounds). Of the 15 non-genotoxic substances
that induced putative preneoplastic (hyperplastic) histopatholog-
ical lesions in the sub-chronic study, thirteen substances (87%)
failed to induce treatment-related tumours in the carcinogenicity
study (False Positive compounds), whereas 2 non-genotoxic sub-
stances (13%) also caused tumours in the carcinogenicity study
(True Positive compounds).
3.1. True Negative (TN) non-genotoxic compounds (Table 2;
Annexes A and B)
Of the 111 TN compounds, thirty-one (28%) did neither exhibit
any effect on organ weight nor induced cellular hypertrophy in any
organ (Annex A).
Eighty of the 111 TN compounds (72%) demonstrated an in-
crease in weight of one or more organs (Annex B; Table 2) such as
liver (n ¼ 69; 86%); kidneys (n ¼ 38; 48%); brain (n ¼ 16; 20%);
spleen (n ¼ 16; 20%); testes (n ¼ 10; 12%); adrenals (n ¼ 8; 8%);
thyroid (n¼ 4; 5%); pituitary (n¼ 2; 2%) or lungs (n¼ 1; 1%), either
or not in combination with cellular hypertrophy (n ¼ 50; 55%).
Cellular hypertrophy wasmainly observed in the liver (n¼ 48) and/
or the thyroid (n ¼ 5).
Table 2
True negative compounds: summary of organ weight increase and cellular hyper-
trophy observed in the sub-chronic studies.
Organ Organ wt increased;
no hypertrophy
Hypertrophy; no
increase in organ wt
Organ wt increased
and hypertrophy
Liver 27 6 42
Kidneys 38 0 0
Brain 16 0 0
Spleen 15 0 0
Testes 10 0 0
Adrenals 8 1 1
Thyroid 5 4 1
Pituitary 2 1 0
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Forty-eight of the 111 TN compounds (43%) induced hepato-
cellular hypertrophy, in most cases (n¼ 42) in combinationwith an
increase in liver weight and occasionally in combination with hy-
pertrophy of the follicular cells of the thyroid, the cells of the zona
glomerulosa of the adrenals or pituitary cells. One compound
(polixetonium chloride) demonstrated epithelial hypertrophy and
inﬂammation in the brain.
Six compounds (7%) demonstrated hepatocellular hypertrophy
without an increase in liver weight.3.1.2. Thyroid
Six compounds induced an increase in thyroid weight, which in
one case was accompanied by hypertrophy of the follicular
epithelial cells. Four compounds induced follicular cell hypertrophy
in the thyroid without an increase in thyroid weight.3.2. True Positive (TP) non-genotoxic compounds (Annex C)
Two (Quintozene and Vinclozolin) non-genotoxic substances
were classiﬁed as True Positive (TP). These substances induced
putative preneoplastic lesions in the thyroid (follicular cell hyper-
plasia) and testes (Leydig cell hyperplasia), respectively, accompa-
nied by an increase in weight of the liver (Quintozene) or liver and
adrenals (Vinclozin) in the sub-chronic study. In the carcinogenicity
studies, Quintozene and Vinclozolin caused follicular cell carci-
nomas and Leydig cell carcinomas, respectively.
Six compounds that were positive or inconclusive for genotox-
icity induced preneoplastic lesions in the 13-week study in the
same organ (stomach; urinary bladder and thyroid) where the tu-
mours developed in the 24-month study.3.3. False Positive (FP) non-genotoxic compounds (Table 3; Annex
D)
Thirteen non-genotoxic compounds caused putative preneo-
plastic (hyperplastic) histopathological changes in the sub-chronic
study, whereas no treatment-related tumours were observed in the
carcinogenicity study.
For the non-genotoxic compounds classiﬁed as FP, the site of
histopathological evidence (cellular hyperplasia) of risk for rat
neoplasia was: the urinary tract (7), the gastrointestinal tract (4)
and the thyroid (3). Five compounds caused a statistically signiﬁ-
cant increase in liver weight that was not accompanied by hepa-
tocellular hypertrophy or hyperplasia. One compound induced
hyperplasia of the esophageal epithelium and the transitional
epithelium of the urinary bladder. In four cases the hyperplasia of
the transitional or tubular epithelium of the urinary bladder or the
kidneys, respectively, was accompanied by an increase in weight of
the kidneys.3.4. False Negative (FN) compounds (Table 4; Annex E)
Thirty-seven non-genotoxic substances were classiﬁed as False
Negative (FN) because they did not exhibit putative preneoplastic
lesions in the 13-week study, but caused treatment-related benign
and/or malignant tumours in the carcinogenicity study.
Eight of these 37 FN compounds induced tumours in the carci-
nogenicity study without inducing any relevant effect (hypertrophy
or organ weight increase) in the sub-chronic study. Four of these 8
compounds induced benign, 2 compounds malignant and 2 com-
pounds benign and malignant tumours in the carcinogenicity
study.
Nineteen other compounds induced benign tumours only,
whereas 3 other substances induced malignant tumours only.
Fifteen compounds induced both benign and malignant tumours.
Malignant tumours occurred most frequently in the liver, thyroid,
pituitary, breast and occasionally in uterus, and incidentally in
nose, Zymbal glands and adrenals.
Four substances (Propyzamide; Tralkoxydim; Imazalil; Chlor-
pyrifos) induced benign tumours in multiple organs; one substance
(C.I. Acid Red) induced malignant tumours in multiple organs and
ﬁve compounds (Prosulfuron; Thiacloprid Tebufenpyrad; Imaze-
thapyr; Ametryn) induced benign and malignant tumours in mul-
tiple organs/tissues.
3.4.1. Benign tumours
The most frequently observed benign tumours were follicular
cell adenomas of the thyroid; hepatocellular adenomas; Leydig cell
adenomas and adenomas of the pituitary gland. An increased
incidence of tubular adenomas of the kidneys, or adenomas of the
prostate were isolated ﬁndings, each induced by different
compounds.
3.4.2. Malignant tumours
Three compounds induced only malignant tumours: i) Spi-
rodiclofen: adenocarcinomas in the uterus; and Cyﬂuthrin and
Tribenuron-methyl: both adenocarcinomas in the mammary gland.
3.4.3. Benign and malignant tumours
Fifteen compounds caused both benign and malignant tumours
in the same (9) or in different organs (6).
3.4.4. Liver
Twenty-eight of the 37 FN compounds showed an increase in
liver weight, either (11) or not (17) accompanied by hepatocellular
hypertrophy in the sub-chronic study. One substance (Tepralox-
ydim) exhibited hepatocellular hypertrophy only. Six of the 11
compounds, which induced both an increase in weight of the liver
and hepatocellular hypertrophy, induced hepatocellular adenomas
(Perﬂuoro-octanesulfonic acid; Dimetheneamide; Tibufenpyrad;
Lactofen; Imazalil; 1,3 Dichlorpropene) or hepatocellular adenomas
and carcinomas (Diclofop-methyl; Diethylhexylphthalate; C.I. Acid
Red 114) in the carcinogenicity study.
Seven compounds induced hepatocellular hypertrophy, all
(except Tepraloxydim) accompanied by an increase in liver weight
in the sub-chronic study but no development of liver tumours in
the carcinogenicity study. Remarkably, all these substances caused
tumours in endocrine organs. Thiazopyr and clofentezine caused
follicular cell adenomas and adenocarcinomas in the thyroid.
Thiacloprid induced thyroid adenomas and uterus adenocarci-
nomas and propylzamide caused thyroid adenomas and Leydig cell
adenomas of the testes. Clodinafop induced prostate adenomas and
tepraloxydin caused benign and malignant phaeochromocytomas
in the medulla of the adrenals.
Table 3
False Positive compounds: summary of the observations in the sub-chronic studies.
Organ Organ wt increased;
no hyperplasia
Hyperplasia;
no increase in
organ wt
Increase in
organ wt and
hyperplasia
Oesophagus/forestomach 0 4 0
Urinary bladder 0 4 0
Thyroid 0 1 2
Kidneys 2 1 2
Liver 5 0 0
Adrenals 1 0 0
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Five compounds caused an increase in thyroid weight and
follicular cell hypertrophy in the sub-chronic study, which was in 3
cases accompanied by benign and in 2 cases by benign and ma-
lignant thyroid tumours in the carcinogenicity study. Overall, thir-
teen compounds induced follicular cell adenomas (8) or follicular
cell adenomas and adenocarcinomas (5) in the thyroid.
3.4.6. Kidneys
Eighteen compounds caused an increase in kidney weight in the
sub-chronic study but no kidney tumours in the carcinogenicity
study. Only one compound (Imazethapyr) caused an increase in
kidney weight in the sub-chronic study accompanied by an
increased incidence of tubular cell adenomas in the kidneys in the
carcinogenicity study.
3.4.7. Adrenals
Five compounds showed an increase in weight of the adrenals
without an increase in the incidence of adrenal phaeochromocy-
tomas in the carcinogenicity study, whereas one compound
(Tepraloxydim) induced an increase in incidence of benign and
malignant phaeochromocytomas in the carcinogenicity study
without an effect on the adrenals in the sub-chronic study.
3.4.8. Testes
One compound (Propyzamide) induced an increase in weight of
the testes in the sub-chronic study which was accompanied by an
increase in incidence of Leydig cell adenomas in the carcinogenicity
study. Four compounds induced Leydig cell adenomas in the car-
cinogenicity study without an effect on weight of the testes in the
sub-chronic study, whereas 2 compounds showed an increase inTable 4
False Negative compounds: summary of the observations in the sub-chronic and carcino
Sub-chronic study
Organ Organ wt increased; no
hypertrophy
Hypertrophy; no increase in organ
wt
In
hy
Liver 17 1 11
Kidneys 17 0 0
Adrenals 4 0 2
Thyroid 1 3 1
Spleen 1 0 0
Brain 7 0 0
Pituitary 0 0 0
Testes 3 0 0
Zymbal gland 0 0 0
Preputial
gland
0 0 0
Breast 0 0 0
Nose 0 0 0
Uterus 0 0 0
Prostate 0 0 0testes weight in the sub-chronic study without the development of
neoplasms in the testes in the carcinogenicity study.
3.4.9. Pituitary
Six compounds induced pituitary adenomas or pituitary ade-
nomas and adenocarcinomas in the carcinogenicity study, without
an effect on weight or histopathology of the pituitary in the sub-
chronic study.
4. Discussion and conclusions
The present retrospective study using rat data from sub-chronic
(13-week) toxicity and carcinogenicity studies obtained from the
EFSA and the ToxRef database was performed to support the hy-
pothesis as put forward by Reddy et al. (2010) and Sistare et al.
(2011), that the absence of any putative preneoplastic lesion in a
sub-chronic (3-month) study may lead to the conclusion that the
test compound investigated is negative for carcinogenicity in rats
and no further long-term study is needed. They based their so
called “whole animal negative predictivity hypothesis” on an
evaluation of pharmaceuticals. We focused on industrial chemicals.
Overall, the regulatory frameworks for industrial chemicals differ in
their information requirements for cancer risk assessment in
comparison to pharmaceuticals. The main differences relevant for
the present study are: the duration of the rat sub-chronic toxicity
study (3 months instead of 6 months), the lack of information on
hormonal perturbation and limited information on the mode of
action. Since we aimed to test the “whole animal negative pre-
dictivity hypothesis” as potential approach for regulatory purposes,
we used in the present study only data on genotoxicity and data
from 3-months toxicity studies. Hundred sixty-three of the 202
chemicals evaluated in the present study were considered negative
for genotoxicity, whereas 39 compounds were considered positive
or inconclusive for genotoxicity. Only the non-genotoxic com-
pounds were included in the present evaluation, since the general
presumption is that in vivo genotoxic compounds are carcinogenic
and are presently only incidentally tested in a carcinogenicity study
in rats.
4.1. True Negative (TN) compounds
A large number of TN compounds induced an increase in
(relative) liver weight. An increase in liver weight may result from a
wide variety of causes such as hyperplasia (of any of the residentgenicity studies.
Carcinogenicity study:
Tumours
creased organ wt and
pertrophy
Benign Benign and
malignant
8 4
2 0
0 1
8 5
0 0
0 0
3 3
4 0
0 1
1 0
0 4
0 1
1 2
1 0
Table 5
Predictivity of the sub-chronic toxicity study for the carcinogenicity of non-
genotoxic chemicals.a
Carcinogenicity
Positive Negative
Sub-chronic toxicity Positive 2 13
Negative 37 111
%
Elimination of studies 91 ¼[(37 þ 111)/
(37 þ 111þ2 þ 13)]  100
False negatives 25 ¼[37/(37 þ 111)]  100
Negative predictivityb 75 ¼[111/(111 þ 37)]  100
Positive predictivityc 13 ¼[2/(2 þ 13)]  100
Sensitivityd 5 ¼[2/(2 þ 37]  100
Speciﬁcitye 90 ¼[111/(111 þ 13)]  100
a The subchronic (3-month) study results were used to categorize a compound as
True Positive (TP); False Positive (FP); False Negative (FN) and True Negative (TN).
b Ability to predict non-carcinogens: [TN/(TN þ FN)]  100.
c Ability to predict rat carcinogens: [TP/(TP þ FP)]  100.
d Ability to detect rat carcinogens: [TP/(TP þ FN)]  100.
e Ability to detect non-carcinogens: [TN/(TN þ FP)]  100.
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of metabolism or cleavage products, neoplasia and congestion
(Carthew et al., 1996; Greaves, 2007). Typically, these changes do
not occur in isolation, so in the absence of overt adverse changes
such as inﬂammation, necrosis or degeneration, it is important to
recognize that an increase in liver weight may be induced by hy-
pertrophy, hyperplasia or a combination of the two (Maronpot
et al., 2010). A xenobiotic that induces an increase in liver weight
of 150% in a sub-chronic study might be considered adverse in the
context of dose setting for longer term studies but would not be
considered adverse in the context of safety evaluation (Carmichael
et al., 1997; Hall et al., 2012). Remarkably, hepatocellular hyper-
plasia did not occur in the ToxRef or EFSA database for any of the
compounds evaluated in the present survey.
In a survey of 139 chemicals used in the agrochemical industry,
Carmichael et al. (1997) demonstrated that a relative increase in
liver weight of 150% of control values was correlated with the
induction of liver tumours in mice. In a similar review of rat studies,
a less statistically signiﬁcant relationship between liver weight and
hepato-carcinogenesis was noted, whereby liver weight increase
alone correctly predicted eight of eleven liver carcinogens (but false
predicted twenty-six chemicals as positives) and failed to predict
three true positives (Carmichael et al., 1997).
Our ﬁndings demonstrate that treatment-related changes in
organ weights, observed in a sub-chronic study with rats, are most
likely non-speciﬁc and therefore should not be considered as a risk
factor for neoplasia.
The term hypertrophy can have various connotations including
an increase inweight of the organ, an increase in the average size of
the cells and even enzyme induction (functionally hypertrophy).
Allen et al. (2004) evaluated the results for 111 chemicals tested by
the National Toxicology Programme. If they applied hepatocellular
necrosis, hepatocellular hypertrophy, hepatocellular cytomegaly
and increased liver weight as predictors for carcinogenicity,
increased liver weight appeared to be themost sensitive parameter.
However, chemicals that produced liver tumours frequently
induced multiple morphological changes. They concluded that the
best single predictor of liver cancer in mice was hepatocellular
hypertrophy. They found no false negatives, but numerous false
positives in their evaluation.
In the present study, eight TN compounds showed an increase in
hepatocellular hypertrophy without an effect on liver weight in the
sub-chronic study. In none of the cases, this was associatedwith the
development of hepatocellular adenomas and/or carcinomas in the
carcinogenicity study. Fifty-four compounds induced an increase in
weight and hepatocellular hypertrophy in the sub-chronic study,
which in only ﬁve cases was associated with hepatocellular ade-
nomas and/or carcinomas in the carcinogenicity study. These
ﬁndings support our starting point to classify hyperthrophy as an
adaptive rather than an adverse putative preneoplastic lesion. If we
had assessed hepatocellular hypertrophy as an indicator for the
development of hepatocellular tumours, 55 compounds would
have been overpredicted as potential liver carcinogens (False Pos-
itive substances). This conﬁrms that liver hypertrophy observed in a
sub-chronic (13-week) study is an unreliable predictor of carcino-
genicity. This is in agreement with the conclusion from the 3th
International ESTP Expert Workshop (Hall et al., 2012) that hepa-
tomegaly as a consequence of hepatocellular hypertrophy without
histologic or clinical pathological alterations indicative of liver
toxicity is an adaptive and non-adverse reaction.
The negative predictivity, the measure of the compounds eval-
uated that did not showany putative preneoplastic lesion in de sub-
chronic studies and were negative in the carcinogenicity studies,
was 75%, whereas the sensitivity, a measure of the sub-chronic
study to predict positive carcinogenicity outcome was only 5%(Table 5). In contrast, the speciﬁcity, the accuracy of the sub-chronic
study to correctly identify non-carcinogens was 90%. Based on the
absence of putative preneoplastic lesions in the sub-chronic study,
91% of the 2-year carcinogenicity studies could have been elimi-
nated at the risk of 37 (23%) FN.
4.2. True Positive (TP) compounds
The positive predictivity (13%) is the percentage of compounds
that showed putative preneoplastic changes in the sub-chronic
study and caused treatment-related tumours in the 24-month
carcinogenicity study.
Two non-genotoxic chemicals were classiﬁed as TP. They
developed putative preneoplastic lesions in thyroid and testes in
the sub-chronic study and malignant tumours (follicular cell car-
cinomas and Leydig cell carcinomas, respectively) in the carcino-
genicity study. The number of TP compounds observed in the
present study is too low to support the conclusion of Reddy et al.
(2010) that the whole animal approach assumes that preneo-
plastic changes at any organ will be indicative for an increase in
tumour incidence in that organ or in any organ at a distant site.
On the contrary, the observation that several of the False Posi-
tive compounds (Table 5) demonstrated hyperplastic histopatho-
logical changes in the sub-chronic study without development of
treatment-related tumours at any site in the carcinogenicity is
more in agreement with the observation of Jacobs (2005) who
concluded, on the basis of an evaluation of 60 pharmaceuticals, that
various short-term indicators for carcinogenicity, such as hyper-
plasia, do not always result in tumours in that tissue, although such
a putative preneoplastic histopathological lesions is generally
considered a sign of potential concern for carcinogenicity.
4.3. False Positive (FP) compounds
Thirteen chemicals induced putative preneoplastic (hyper-
plastic) histopathological changes in the epithelium of the
oesophagus/forestomach, the kidneys/urinary bladder or the thy-
roid, either or not accompanied by an increase in weight of that
organ, whereas no tumours occurred in the carcinogenicity study,
neither in the same organ nor in an organ at distant site.
The equivocal ﬁndings observed in the present paper with TP
and FP compounds support the conclusion of Reddy et al. (2010)
that more research is needed in order to achieve understanding
of the biological links between putative preneplastic lesions
R.A. Woutersen et al. / Regulatory Toxicology and Pharmacology 81 (2016) 242e249248observed in a sub-chronic study and tumours developing at distant
organ sites in the carcinogenicity study.
4.4. False Negative (FN) compounds
Since it is generally accepted that the intention of screening
assays should be conservative, it is most important that the number
of FNs with respect to human carcinogens should be as low as
possible. In the present study, 37 compounds were classiﬁed as FN
because they did not show putative preneoplastic lesions in the 13-
week study, but caused treatment-related tumours in the carci-
nogenicity study. These compounds are of concern with regard to
the acceptability of the negative predictivity of the whole animal
approach stating that the absence of evidence of putative preneo-
plastic lesions in all tissues in the 13-week study may serve as a
strong negative predictor of tumour outcome in the carcinogenicity
study.
Thirty-three of the 37 FN substances induced benign tumours or
benign and malignant tumours which are considered not relevant
for the human situation (Williams et al., 2014): phaeochromocy-
tomas of the adrenal medulla (Greim et al., 2009); forestomach
tumours (Kroes andWester, 1986); hepatocellular tumours induced
by peroxisome proliferators (IARC, 1995; Williams and Perone,
1996; Klaunig et al., 2003); ﬁbroadenomas of the mammary
gland (Russo et al., 1990); pituitary tumours (adenohypophysis
tumours) (Gold et al., 2001); Leydig cell (interstitial cell) tumours of
the testes (Cook et al., 1999; Prentice and Meikle, 1995); thyroid
tumours (Alison et al., 1994; Rice et al., 1999); urinary bladder tu-
mours (Cohen, 1998; Cohen and Ellwein, 1991; Cohen et al., 2004;
Rice et al., 1999) and uterus tumours (endometrial stromal
polyps) (Davis, 2012).
When the chemicals that gave rise to tumours generally
considered not relevant for human risk assessment (n ¼ 33), were
moved from the FN to the TN category (leading to ﬁgure 37 in
Table 5 should be replaced by 4; and 111 by 144), the negative
predictivity of the sub-chronic study for the absence of carcinoge-
nicity (ability to predict non-carcinogens) amounts to 97% and the
speciﬁcity (the ability to detect non-carcinogens) to 92%. This in-
dicates that over 90% of the 24-month carcinogenicity studies could
have been avoided when the negative predictivity of the whole
animal approach (Reddy et al., 2010; Sistare et al., 2011) would have
been applied, which reduced a remarkable number of animals.
The sensitivity (and positive predictivity) of the sub-chronic (13-
week) toxicity studies for predicting tumour outcome based on the
putative preneoplastic lesions observed in the sub-chronic study
was poor, which is in agreement with others who showed that this
approach is not useful (Jacobs, 2005; Reddy et al., 2010; Sistare
et al., 2011).
Our results demonstrate that sub-chronic (13-week) studies can
appropriately classify a non-genotoxic chemical into three
categories:
i) highly unlikely to be tumourigenic when no histopatholog-
ical risk factor for neoplastic lesions is observed in the sub-
chronic study in any tissue;
ii) likely tumourigenic in rats, but the putative preneoplastic
lesions observed in the sub-chronic study may give rise to a
type of tumour in the carcinogenicity study that is not rele-
vant for humans; therefore, a carcinogenicity study has no
additional value;
iii) tumourigenicity in humans is uncertain but the putative
preneoplastic lesions observed in the sub-chronic study
point to the added value of a carcinogenicity study.
Overall, the results of the present retrospective study supportthe negative predictivity of thewhole animal approach as proposed
by Reddy et al. (2010) and Sistare et al. (2011): chemicals showing
no histopathological risk factors for neoplastic lesions in any tissue
in rats in sub-chronic (13-week) toxicity studies maymost likely be
considered non-carcinogens and do not require further testing in a
carcinogenicity study.
This is in agreement with the approach followed by the Euro-
pean Chemical Agency in Helsinki (EC, 2007). Under REACH, a
carcinogenicity bioassay is rarely requested. Relevant factors that
may trigger a two-year carcinogenicity bioassay in this respect
include: i) genotoxicity (germ cell mutagen category 2); ii) evidence
of treatment-related hyperplasia and/or preneoplastic lesions in
the sub-chronic study; iii) previous demonstration of carcinogenic
potential in the chemical class or product that is considered rele-
vant to humans; iv) widespread use or evidence of frequent long-
term human exposure.
For risk assessment of plant protection products, however, data
from carcinogenicity studies are required (EC, 2013). Modiﬁcation
of these requirements with the ‘whole animal negative approach’
would save large numbers of animals (up to 400 or 500 per study),
time and costs without compromising human safety.
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